Published in Clin Cancer Res on May 01, 1997
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90
Triggering DTH and CTL activity by fd filamentous bacteriophages: role of CD4+ T cells in memory responses. J Biomed Biotechnol (2010) 0.78
Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines. J Biomed Biotechnol (2011) 0.77
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology (1968) 11.20
Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol (1974) 11.12
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Intrinsically disordered protein. J Mol Graph Model (2001) 8.54
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. J Exp Med (1974) 5.37
V beta-specific stimulation of human T cells by staphylococcal toxins. Science (1989) 5.34
Localization of mouse isoantigens on the cell surface as revealed by immunofluorescence. Immunology (1967) 5.10
Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. J Immunol (1987) 5.07
Specific in vitro cytotoxicity of thymus-derived lymphocytes sensitized to alloantigens. Nature (1970) 4.84
Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity. J Exp Med (1983) 4.47
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (1999) 3.75
Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J Immunol (1985) 3.47
Intrinsic protein disorder in complete genomes. Genome Inform Ser Workshop Genome Inform (2000) 3.47
Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45
Shift in the prevalent human rotavirus detected by ribonucleic acid segment differences. Infect Immun (1980) 3.34
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide. Nature (1987) 3.10
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Presence of two distinct types of rotavirus in infants and young children hospitalized with acute gastroenteritis in Mexico City, 1977. J Infect Dis (1979) 2.84
Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J (1971) 2.82
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol (1991) 2.67
Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC. J Immunol (1978) 2.65
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med (1998) 2.58
Generation of cytotoxic T lymphocytes in vitro. II. Effect of repeated exposure to alloantigens on the cytotoxic activity of long-term mixed leukocyte cultures. J Exp Med (1974) 2.52
Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med (1980) 2.50
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
Selectively increased production of interferon-gamma by subsets of Lyt-2+ and L3T4+ T cells identified by expression of Pgp-1. J Immunol (1987) 2.39
Protein disorder and the evolution of molecular recognition: theory, predictions and observations. Pac Symp Biocomput (1998) 2.37
Thymus-derived (T) cell immunoglobulins. Presence of a receptor site for IgG and absence of large amounts of "buried" Ig determinants on T cells. J Exp Med (1972) 2.35
Quantitation and cloning of cytolytic T lymphocytes and their precursors. Immunol Rev (1980) 2.32
Clinical management of field worker organophosphate poisoning. West J Med (1985) 2.27
A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature (1988) 2.26
Isolation of cDNA clones encoding HLA-DR alpha chains. Proc Natl Acad Sci U S A (1982) 2.17
Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations. J Exp Med (1983) 2.16
CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature (1995) 2.15
Cellular and humoral response to transplantation antigens. I. Development of alloantibody-forming cells and cytotoxic lymphocytes in the graft-versus-host reaction. J Exp Med (1971) 2.13
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
The immunogenicity of antigen bound to the plasma membrane of macrophages. J Exp Med (1970) 2.08
Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res (1989) 2.03
An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol (1992) 2.03
In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (1974) 1.96
TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs. J Biol Chem (2001) 1.96
Persistence of antigen on the surface of macrophages. Nature (1969) 1.95
Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool. Proc Natl Acad Sci U S A (1981) 1.91
Surface markers of cloned human T cells with various cytolytic activities. J Exp Med (1981) 1.87
Comparison of the immune responsiveness of NZB and NZB X NZW F1 hybrid mice with that of other strains of mice. J Exp Med (1969) 1.87
Subsets of human Ia-like molecules defined by monoclonal antibodies. Mol Immunol (1981) 1.87
Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature (1987) 1.85
UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation. EMBO J (2001) 1.81
Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer (1995) 1.81
Denitrifying Pseudomonas aeruginosa: some parameters of growth and active transport. Appl Environ Microbiol (1978) 1.79
Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol (2001) 1.77
Isolation of distinct cDNA clones encoding HLA-DR beta chains by use of an expression assay. Proc Natl Acad Sci U S A (1982) 1.77
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol (1986) 1.74
T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74
Separation of stages in the development of the "T" cells involved in cell-mediated immunity. J Exp Med (1972) 1.73
The function of macrophages in the immune response. Semin Hematol (1970) 1.71
Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol (2000) 1.68
H-2-restricted cytolytic T lymphocytes specific for HLA display T cell receptors of limited diversity. J Exp Med (1992) 1.64
Trypsin activation pathway of rotavirus infectivity. J Virol (1996) 1.63
Clonal heterogeneity in the functional requirement for Lyt-2/3 molecules on cytolytic T lymphocytes (CTL): possible implications for the affinity of CTL antigen receptors. Immunol Rev (1982) 1.63
Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med (1983) 1.63
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med (2000) 1.62
Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells. Eur J Immunol (1982) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
In vitro cytotoxic activity of thymus cells sensitized to alloantigens. Nature (1970) 1.57
Phenotypic identification of memory cytolytic T lymphocytes in a subset of Lyt-2+ cells. J Immunol (1987) 1.56
The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules. J Exp Med (1992) 1.56
An evolutionary conserved mechanism of T cell activation by microbial toxins. Evidence for different affinities of T cell receptor-toxin interaction. J Immunol (1991) 1.55
Characterisation and separation of mouse lymphocyte subpopulations responding to phytohemagglutinin and pokeweed mitogens. Cell Immunol (1973) 1.55
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53